Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV003142548 | SCV003808558 | likely pathogenic | Hyperammonemia, type III | 2022-05-31 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003142548 | SCV003835017 | uncertain significance | Hyperammonemia, type III | 2021-12-14 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004701010 | SCV005203499 | uncertain significance | not specified | 2024-07-16 | criteria provided, single submitter | clinical testing | Variant summary: NAGS c.872T>A (p.Ile291Asn) results in a non-conservative amino acid change located in the Aspartate/glutamate/uridylate kinase domain (IPR001048) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 247922 control chromosomes. c.872T>A has been reported in the homozygous state in multiple related individuals in the literature affected with clinical features NAGS deficiency (example, Sancho-Vaello_2016), however the clinical course was late-onset/mild, and follow up assessments described phenotypes as "normal" and not requiring N-carbamyl-L-glutamate therapy. These data indicate that the variant may be associated with a mild, hypomorphic, and/or partial presentation of disease which may be influenced by environmental factors. Multiple publications report experimental in vitro evidence evaluating an impact on protein function in both bacterial and human-derived models of the enzyme encoded by NAGS. The most pronounced variant effect results in 30%-50% of normal enzyme activity, and thermal instability has also been noted (example, Sancho-Vaello_2016, Gougeard_2024). The following publications have been ascertained in the context of this evaluation (PMID: 27570737, 27037498, 38740568). ClinVar contains an entry for this variant (Variation ID: 2432020). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. |